Inhibitors of influenza viruses replication

US10039762B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10039762-B2
Application numberUS-201715718186-A
CountryUS
Kind codeB2
Filing dateSep 28, 2017
Priority dateJun 17, 2009
Publication dateAug 7, 2018
Grant dateAug 7, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

First claim

Opening claim text (preview).

What is claimed is: 1. A method preparing a compound of formula 1070: or a pharmaceutically acceptable salt thereof, comprising the steps of: i) reacting a compound having the formula: with to form a compound having the formula: and ii) deprotecting the tosyl group to form the compound of formula 1070 or a pharmaceutically acceptable salt thereof. 2. A method preparing a compound of formula 1070: or a pharmaceutically acceptable salt thereof, comprising the steps of: i) reacting a compound of formula with a compound of formula to form a compound having the formula: and ii) deprotecting the tosyl group to form the compound of formula 1070 or a pharmaceutically acceptable salt thereof.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Immunostimulants · CPC title

  • for influenza or rhinoviruses · CPC title

  • Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

  • C07D401/10Primary

    linked by a carbon chain containing aromatic rings · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10039762B2 cover?
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically a…
Who is the assignee on this patent?
Vertex Pharma
What technology area does this patent fall under?
Primary CPC classification C07D401/10. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).